JP7601788B2 - チロシンキナーゼの複素環式阻害剤 - Google Patents

チロシンキナーゼの複素環式阻害剤 Download PDF

Info

Publication number
JP7601788B2
JP7601788B2 JP2021563139A JP2021563139A JP7601788B2 JP 7601788 B2 JP7601788 B2 JP 7601788B2 JP 2021563139 A JP2021563139 A JP 2021563139A JP 2021563139 A JP2021563139 A JP 2021563139A JP 7601788 B2 JP7601788 B2 JP 7601788B2
Authority
JP
Japan
Prior art keywords
compound
egfr
alkyl
mmol
her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021563139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529518A5 (enExample
JP2022529518A (ja
Inventor
ヘイマック ジョン
ロビショー ジャクリーヌ
ニルソン モニーク
ジョーンズ フィリップ
クロス ジェイソン
セロフ ジェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2022529518A publication Critical patent/JP2022529518A/ja
Publication of JP2022529518A5 publication Critical patent/JP2022529518A5/ja
Application granted granted Critical
Publication of JP7601788B2 publication Critical patent/JP7601788B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021563139A 2019-04-25 2020-04-24 チロシンキナーゼの複素環式阻害剤 Active JP7601788B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838696P 2019-04-25 2019-04-25
US62/838,696 2019-04-25
PCT/US2020/029849 WO2020219904A1 (en) 2019-04-25 2020-04-24 Heterocyclic inhibitors of tyrosine kinase

Publications (3)

Publication Number Publication Date
JP2022529518A JP2022529518A (ja) 2022-06-22
JP2022529518A5 JP2022529518A5 (enExample) 2023-05-02
JP7601788B2 true JP7601788B2 (ja) 2024-12-17

Family

ID=72941423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563139A Active JP7601788B2 (ja) 2019-04-25 2020-04-24 チロシンキナーゼの複素環式阻害剤

Country Status (7)

Country Link
US (1) US11365189B2 (enExample)
EP (1) EP3962908B1 (enExample)
JP (1) JP7601788B2 (enExample)
CN (2) CN114026083B (enExample)
AU (1) AU2020261423B2 (enExample)
CA (1) CA3137901A1 (enExample)
WO (1) WO2020219904A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022511800A (ja) 2018-12-06 2022-02-01 アースローシ セラピューティクス，インク． 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
US11365189B2 (en) 2019-04-25 2022-06-21 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of tyrosine kinase
WO2021127397A1 (en) * 2019-12-19 2021-06-24 Black Diamond Therapeutics, Inc. Nitrogen heterocyclic compounds and methods of use
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
KR20220147021A (ko) * 2021-04-22 2022-11-02 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도
WO2022266426A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof
WO2022266425A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 3-cyano-quinoline derivatives and uses thereof
WO2023028054A1 (en) * 2021-08-24 2023-03-02 Arthrosi Therapeutics, Inc. Quinazoline compounds for treatment of disease
CN115894486B (zh) * 2021-09-30 2024-02-09 北京赛特明强医药科技有限公司 一种氢化吡啶并喹唑啉类化合物、组合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529115A (ja) 2007-06-05 2010-08-26 ハンミ ファーム． シーオー．， エルティーディー． 癌細胞成長抑制用新規アミド誘導体
WO2015154725A1 (zh) 2014-04-11 2015-10-15 四川海思科制药有限公司 喹唑啉衍生物及其制备方法和在医药上的应用
JP2016531937A (ja) 2013-09-28 2016-10-13 正大天晴薬業集団股▲分▼有限公司Ｃｈｉａ Ｔａｉ Ｔｉａｎｑｉｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． キナゾリン誘導体及びその製造方法
WO2018036539A1 (zh) 2016-08-25 2018-03-01 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐的晶体
JP2018508583A (ja) 2015-03-20 2018-03-29 正大天晴薬業集団股▲分▼有限公司Ｃｈｉａ Ｔａｉ Ｔｉａｎｑｉｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． キナゾリン誘導体の塩およびその製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ536114A (en) 2002-03-30 2007-11-30 Boehringer Ingelheim Pharma 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
CN112040952B (zh) * 2018-02-20 2023-03-31 苏州韬略生物科技股份有限公司 用作激酶抑制剂的取代的喹啉
US11365189B2 (en) 2019-04-25 2022-06-21 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of tyrosine kinase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529115A (ja) 2007-06-05 2010-08-26 ハンミ ファーム． シーオー．， エルティーディー． 癌細胞成長抑制用新規アミド誘導体
JP2016531937A (ja) 2013-09-28 2016-10-13 正大天晴薬業集団股▲分▼有限公司Ｃｈｉａ Ｔａｉ Ｔｉａｎｑｉｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． キナゾリン誘導体及びその製造方法
WO2015154725A1 (zh) 2014-04-11 2015-10-15 四川海思科制药有限公司 喹唑啉衍生物及其制备方法和在医药上的应用
JP2018508583A (ja) 2015-03-20 2018-03-29 正大天晴薬業集団股▲分▼有限公司Ｃｈｉａ Ｔａｉ Ｔｉａｎｑｉｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． キナゾリン誘導体の塩およびその製造方法
WO2018036539A1 (zh) 2016-08-25 2018-03-01 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐的晶体

Also Published As

Publication number Publication date
CN118852118A (zh) 2024-10-29
AU2020261423B2 (en) 2026-01-29
CN114026083A (zh) 2022-02-08
EP3962908A1 (en) 2022-03-09
EP3962908B1 (en) 2026-08-12
CA3137901A1 (en) 2020-10-29
US11365189B2 (en) 2022-06-21
CN114026083B (zh) 2024-07-09
WO2020219904A1 (en) 2020-10-29
EP3962908A4 (en) 2022-10-26
US20200354343A1 (en) 2020-11-12
JP2022529518A (ja) 2022-06-22
AU2020261423A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
JP7579402B2 (ja) 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物
AU2020261423B2 (en) Heterocyclic inhibitors of tyrosine kinase
US12186324B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
KR102653599B1 (ko) 질환 치료용 mct4 저해제
US11690850B2 (en) Inhibitors of receptor interacting protein kinase I for the treatment of disease
CN104606194A (zh) Pde4的双环杂芳基抑制剂
US12559497B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
US20220194940A1 (en) Heterocyclic inhibitors of tyrosine kinase
US12540139B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
WO2018213777A1 (en) Heterocyclic inhibitors of kdm5 for the treatment of disease
US20210361773A1 (en) Compounds and methods for selective proteolysis of glucocorticoid receptors
HK40039574A (en) Ptpn11(shp2) inhibitors
HK40015139A (en) Heterocyclic inhibitors of mct4
HK40015139B (en) Heterocyclic inhibitors of mct4
CN101528228A (zh) Pde4的双环杂芳基抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230424

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240823

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241205

R150 Certificate of patent or registration of utility model

Ref document number: 7601788

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150